Technische Daten
Change(s) made:Complete revision
Status:Research Use Only (RUO)
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of human PMSA
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092)
Zelluläre Lokalisation:Cytoplasmic, membranous
Kontrolle:Prostate, prostate cancer
Synonyme:FOLH, PMSA, Cell growth inhibiting protein 27, FGCP, Folate hydrolase 1, folate hydrolase, Folate hydrolase prostate specific membrane antigen 1, FOLH 1, FOLH, FOLH1, Folylpoly gamma glutamate carboxypeptidase, GCP 2, GCP II, GCP2, GCPII, glutamate carboxylase II, Glutamate carboxypeptidase 2, glutamate carboxypeptidase II, Membrane glutamate carboxypeptidase, mGCP, N acetylated alpha linked acidic dipeptidase 1, N acetylated alpha linked acidic dipeptidase I, NAALAD 1, NAALAD1, NAALAdase, NAALADase I, prostate specific membrane antigen, PSM, pteroylpoly gamma glutamate carboxypeptidase.
Verfügbar in folgenden Ländern:worldwide

PSMA is a zinc metalloenzyme/ class II membrane glycoprotein that resides in membranes. It is mainly expressed in four tissues of the body, including prostate epithelium, the proximal tubules of the kidney, the jejunal brush border of the small intestine and ganglia of the nervous system. Human PSMA is highly expressed in the prostate, roughly a hundred times greater than in most other tissues. In some prostate cancers, PSMA is the second-most upregulated gene product, with an 8- to 12-fold increase over levels in noncancerous prostate cells. Because of this high expression, PSMA is being developed as potential biomarker for therapy and imaging of some cancers. In human prostate cancer, the higher expressing tumors are associated with quicker time to progression and a greater percentage of patients suffering relapse.